BTIG Research Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price

Monopar Therapeutics (NASDAQ:MNPR) had its price objective hoisted by BTIG Research from $87.00 to $104.00 in a report published on Thursday, Marketbeat reports. They currently have a buy rating on the stock.

MNPR has been the subject of several other reports. HC Wainwright started coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $74.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, August 27th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, September 16th. Raymond James Financial initiated coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 price objective on the stock. Finally, Lake Street Capital assumed coverage on shares of Monopar Therapeutics in a research note on Tuesday. They set a “buy” rating and a $106.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $82.33.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $77.44 on Thursday. Monopar Therapeutics has a 52 week low of $4.50 and a 52 week high of $79.80. The firm has a market capitalization of $477.80 million, a price-to-earnings ratio of -23.26 and a beta of 1.20. The company has a 50 day moving average price of $43.86 and a 200 day moving average price of $39.04.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. Equities analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Chandler Robinson sold 16,800 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares in the company, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the business’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the sale, the director owned 11,486 shares of the company’s stock, valued at $459,440. The trade was a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock valued at $1,700,160 over the last quarter. Insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNPR. Police & Firemen s Retirement System of New Jersey bought a new position in Monopar Therapeutics in the 2nd quarter worth approximately $34,000. AlphaQuest LLC acquired a new stake in Monopar Therapeutics during the first quarter worth about $44,000. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics during the second quarter worth $80,000. Finally, New York State Common Retirement Fund bought a new stake in Monopar Therapeutics in the second quarter valued at about $104,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.